B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia

• Published in: European journal of medical research 2023-03, Vol.28 (1), p.129-129, Article 129
• Main Authors: Fan, Shuangshuang, Wang, Tian, You, Fengtao, Zhang, Tingting, Li, Yafen, Ji, Cheng, Han, Zhichao, Sheng, Binjie, Zhai, Xiaochen, An, Gangli, Meng, Huimin, Yang, Lin
• Format: Article
• Language: English
• Subjects: Acute myeloid leukaemia; Animals; Antibodies; Antigens; B7-H3; Cancer therapies; Cell Line, Tumor; Chemotherapy; Chimeric antigen receptor-T cell; Cytokines; Cytokines - metabolism; Disease; Flow cytometry; Immunotherapy; Immunotherapy, Adoptive - methods; Laboratories; Leukemia; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - therapy; Lymphocytes; Metastasis; Mice; Proteins; Receptors, Chimeric Antigen - genetics; Receptors, Chimeric Antigen - metabolism; Remission (Medicine); T cells; T-Lymphocytes - metabolism; Tumors
• ISSN: 2047-783X; 0949-2321; 2047-783X
• DOI: 10.1186/s40001-023-01049-y

Chimeric antigen receptor (CAR)-T cell therapy is a novel type of immunotherapy. However, the use of CAR-T cells to treat acute myeloid leukaemia (AML) has limitations. B7-H3 is expressed in several malignancies, including some types of AML cells. However, its expression in normal tissues is low. Therefore, B7-H3 is ideal for targeted AML therapy. First, we constructed B7-H3 CAR that can target B7-H3, and then constructed B7-H3-CAR-T cells in vitro, which were co-incubated with six AML cell lines expressing different levels of B7-H3, respectively. The toxicity and cytokines were detected by flow cytometry. In vivo, AML model was established in B-NSG mice to study the toxicity of B7-H3-CAR T on AML cells. In vitro functional tests showed that B7-H3-CAR-T cells were cytotoxic to B7-H3-positive AML tumor cells and had good scavenging effect on B7-H3-expressing AML cell lines, and the cytokine results were consistent. In vivo, B7-H3-CAR-T cells significantly inhibited tumor cell growth in a mouse model of AML, prolonging mouse survival compared with controls. B7-H3-CAR-T cells may serve as a novel therapeutic method for the targeted treatment of AML.